Prostaglandin E1
Based on 22 publication(s) in Google Scholar
Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.76%
- CAS. Nr.: 745-65-3
- Formel: C20H34O5
- Molecular Weight:354.48
-
Speicherung:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Prostaglandin E1
More- Exploration. 2025 Mar 6;5(3):20240084. [Abstract]
- Nat Cell Biol. 2024 Jul;26(7):1110-1123. [Abstract]
- Acta Pharm Sin B. 2022 Aug;12(8):3427-3447. [Abstract]
- Adv Sci (Weinh). 2026 May;13(25):e15933. [Abstract]
- J Control Release. 2019 May 6;304:233-241. [Abstract]
- Small Struct. 2023 Mar 8.
- Mater Today Bio. 2025 Apr 9:32:101744. [Abstract]
- Mater Today Bio. 2025 Mar 29:32:101719. [Abstract]
- Mater Today Bio. 2022 Dec 5:18:100512. [Abstract]
- Nano Res. 11, 6086-6101(2018).
- Int J Biol Macromol. 2025 May 7:144068. [Abstract]
- Chin Med. 2026 Jan 8;21(1):16. [Abstract]
- Colloids Surf B Biointerfaces. 2024 Feb:234:113680. [Abstract]
- Am J Respir Cell Mol Biol. 2025 Feb 28. [Abstract]
- J Thromb Haemost. 2024 May;22(5):1463-1474. [Abstract]
- Int J Mol Sci. 2022 Oct 15;23(20):12345. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Stem Cell Rev Rep. 2026 Jan 30;22(3):1325-1340.
- J Cardiovasc Pharmacol Ther. 2026 Jan-Dec:31:10742484261452727. [Abstract]
- Pigment Cell Melanoma Res. 2025 Sep;38(5):e70048. [Abstract]
- Curr Proteomics. 2026 Mar 25.
- Oxid Med Cell Longev. 2022 Jan 17:2022:3087198. [Abstract]
Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
EP |
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Oocyte | IC50 |
0.0358 μM
Compound: Prostaglandin E1
|
TP_TRANSPORTER: inhibition of PGD2 uptake in Xenopus laevis oocytes
TP_TRANSPORTER: inhibition of PGD2 uptake in Xenopus laevis oocytes
|
[PMID: 10973807] |
| Platelet | ED50 |
0.02 mg/kg
Compound: PGE1
|
Inhibition of bovine collagen-induced platelet aggregation isolated from ip treated Hartley guinea pig after 1 hr treatment
Inhibition of bovine collagen-induced platelet aggregation isolated from ip treated Hartley guinea pig after 1 hr treatment
|
[PMID: 214552] |
| Vero C1008 | CC50 |
>40 μM
Compound: Alprostadil
|
Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm)
Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm)
|
10.1101/2020.04.03.023846 |
| Vero C1008 | EC50 |
5.39 μM
Compound: Alprostadil
|
Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days
Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days
|
10.1101/2020.04.03.023846 |
Prostaglandin E1 (1 nM-10 μM; 48 h) concentration-dependently reduces HUVECs proliferation (up to 100% inhibition) in the presence of VEGF (20 ng/mL), with an IC50 of 400 nM[2].
Prostaglandin E1 (0.01-10 μM; 6 h) inhibits VEGF-induced HUVECs migration in a concentration dependent manner, with an IC50 of 500 nM[2].
Prostaglandin E1 (1-5 μM; 12-18 h) inhibits in vitro angiogenesis[2].
Prostaglandin E1 (0.01-10 μM; 20 min) increases intracellular cAMP levels in HUVECs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57/bl6 female mice (6-8 weeks) were injected with Matrigel supplemented with aFGF and heparin[2]
-
Dosage:20 ng/day/animal
-
Administration:Minipump placed subcutaneously for 4 days
-
Result:Visibly reduced the neovascularization process.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 745-65-3
-
Appearance Solid
-
Molecular Weight 354.48
-
Formel C20H34O5
-
Color White to off-white
-
SMILES
CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C(C[C@H]1O)=O)CCCCCCC(O)=O
-
Synonyms
Alprostadil; PGE1
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
Exploration
Surface-Anchored Ticagrelor Gelatin Nanoparticles-Platelets System for Enhanced Anti-PD-L1 Therapy Response and Boosted Chemotherapeutic Efficacy of Nanomedicines. [Abstract]2025 Mar 6;5(3):20240084. PMID: 40585768 -
Nat Cell Biol
2024 Jul;26(7):1110-1123. PMID: 38997457 -
Acta Pharm Sin B
Nanoplateletsomes restrain metastatic tumor formation through decoy and active targeting in a preclinical mouse model. [Abstract]2022 Aug;12(8):3427-3447. PMID: 35967283 -
Adv Sci (Weinh)
Activated Platelet-Released Heat Shock Protein 90α Triggers Autophagy-Dependent Neutrophil Extracellular Trap Formation and Amplifies Sepsis. [Abstract]2026 May;13(25):e15933. PMID: 41732887 -
J Control Release
Platelets as platforms for inhibition of tumor recurrence post-physical therapy by delivery of anti-PD-L1 checkpoint antibody. [Abstract]2019 May 6;304:233-241. PMID: 31071371 -
-
Mater Today Bio
2025 Apr 9:32:101744. PMID: 40275952 -
Mater Today Bio
2025 Mar 29:32:101719. PMID: 40236816 -
Mater Today Bio
Platelet-derived extracellular vesicles ameliorate intervertebral disc degeneration by alleviating mitochondrial dysfunction. [Abstract]2022 Dec 5:18:100512. PMID: 36536658 -
-
Int J Biol Macromol
FKBP5 inhibitor suppresses platelet activation and thrombosis by inhibiting IKBKE/PI3K/Rap1 pathway. [Abstract]2025 May 7:144068. PMID: 40345291 -
Chin Med
Ferulic acid in combination with ginsenoside Rb1 alleviates myocardial no-reflow by inhibiting platelet HMGB1 release and NET formation. [Abstract]2026 Jan 8;21(1):16. PMID: 41501834 -
Colloids Surf B Biointerfaces
Platelet membrane-derived biomimetic microbubbles with enhanced targeting ability for the early detection of myocardial ischemia-reperfusion injury. [Abstract]2024 Feb:234:113680. PMID: 38101143 -
Am J Respir Cell Mol Biol
GP IIb/IIIa-ICAM-1 Mediated Platelet-Endothelial Adhesion Exacerbates Pulmonary Hypertension. [Abstract]2025 Feb 28. PMID: 40019848 -
J Thromb Haemost
Extracellular vesicles from activated platelets possess a phospholipid-rich biomolecular profile and enhance prothrombinase activity. [Abstract]2024 May;22(5):1463-1474. PMID: 38266680 -
Int J Mol Sci
Coenzyme Q10 Attenuates Human Platelet Aggregation Induced by SARS-CoV-2 Spike Protein via Reducing Oxidative Stress In Vitro. [Abstract]2022 Oct 15;23(20):12345. PMID: 36293203 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
-
J Cardiovasc Pharmacol Ther
Alterations of Platelet MicroRNAs Associated With Dapagliflozin Treatment in Individuals With Type 2 Diabetes Mellitus. [Abstract]2026 Jan-Dec:31:10742484261452727. PMID: 42165435 -
Pigment Cell Melanoma Res
2025 Sep;38(5):e70048. PMID: 40913269 -
-
Oxid Med Cell Longev
2022 Jan 17:2022:3087198. PMID: 35082966
Lösungsmittel & Löslichkeit
Ethanol : 100 mg/mL (282.10 mM; Need ultrasonic)
DMSO : 100 mg/mL (282.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Kiriyama M, et, al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. [Content Brief]
[2]. Cattaneo MG, et, al. Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay. Br J Pharmacol. 2003 Jan;138(2):377-85. [Content Brief]
[3]. Hauck EW, et, al. Prostaglandin E1 long-term self-injection programme for treatment of erectile dysfunction--a follow-up of at least 5 years. Andrologia. 1999;31 Suppl 1:99-103. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.8210 mL | 14.1052 mL | 28.2103 mL | 70.5258 mL |
| 5 mM | 0.5642 mL | 2.8210 mL | 5.6421 mL | 14.1052 mL | |
| 10 mM | 0.2821 mL | 1.4105 mL | 2.8210 mL | 7.0526 mL | |
| 15 mM | 0.1881 mL | 0.9403 mL | 1.8807 mL | 4.7017 mL | |
| 20 mM | 0.1411 mL | 0.7053 mL | 1.4105 mL | 3.5263 mL | |
| 25 mM | 0.1128 mL | 0.5642 mL | 1.1284 mL | 2.8210 mL | |
| 30 mM | 0.0940 mL | 0.4702 mL | 0.9403 mL | 2.3509 mL | |
| 40 mM | 0.0705 mL | 0.3526 mL | 0.7053 mL | 1.7631 mL | |
| 50 mM | 0.0564 mL | 0.2821 mL | 0.5642 mL | 1.4105 mL | |
| 60 mM | 0.0470 mL | 0.2351 mL | 0.4702 mL | 1.1754 mL | |
| 80 mM | 0.0353 mL | 0.1763 mL | 0.3526 mL | 0.8816 mL | |
| 100 mM | 0.0282 mL | 0.1411 mL | 0.2821 mL | 0.7053 mL |
Prostaglandin E1 Related Classifications
HY-B0131 Related Classifications
Powered by Bioz